Phase III Results for Gilead Hep C Combo
"Gilead unveiled a package of stellar late-stage cure rates for its closely watched hepatitis C combination of the newly approved "nuke" Sovaldi (sofosbuvir) and the NS5A inhibitor ledipasvir, putting it on a short path to the FDA with a new drug application planned for the first quarter of the coming year.
The success of the combo will speed up the likely near-term approval of a new therapy that can offer a large portion of genotype 1 hepatitis C patients a quick "cure" without interferon or ribavirin--the holy grail of this R&D field over the past few years. As a result, current standards of care are being swept away as Gilead leads a pack of avid rivals angling for a share of a megablockbuster market. Bristol-Myers Squibb and AbbVie are following closely behind Gilead in the race to the market."To read more, please visit: Gilead races to the FDA with stellar PhIII results for its breakthrough hep C combo - FierceBiotech
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2014 Infectious Diseases Society of America